Navigation Links
Transdermal HRT not cardioprotective in postmenopausal women with CAD ,,

Transdermal hormone replacement therapy (HRT) does not reduce the risk of cardiac events in postmenopausal women with existing coronary artery disease (CAD). In the PHASE trial (Papworth HRT Atherosclerosis Study), researchers randomized 255 postmenopausal women with angiographically proven coronary artery disease to receive either transdermal HRT--17-beta-estradiol with or without cyclic norethisterone--or no hormone replacement therapy. The women were followed for 4 years. Overall, 134 women received hormone replacement therapy. Of these, 58 had a previous hysterectomy. The other 121 women served as controls.

On intention-to-treat analysis, there was no statistical difference in the incidence of unstable angina requiring hospitalization, MI or premature death from heart disease in women receiving HRT and women not receiving the therapy. Respectively, the average event rates were 15.6 and 12.6 per 100 patient-years. Results from the PHASE study also seem to indicate an increased risk of thromboembolic complications, such as stroke, with HRT. This observation is supported by results from the HERS study, a randomized trial carried out in the US that included 3000 women, and was designed to assess the cardioprotective effect of combined HRT in women with documented CAD. It may therefore be appropriate that women with proven coronary artery disease should not commence HRT. Nevertheless, women receiving HRT for more than 2 years should continue.
'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Transdermal Vaccine Effective in Treating Alzheimers Disease in Mice
3. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
4. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
5. Enlarged waistline may predict atherogenesis for postmenopausal women
6. Research explains why postmenopausal women accumulate abdominal fat.
7. Testosterone Therapy can improve sexual function in postmenopausal women
8. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
9. Starvation in pregnant women can cause heart disease to their children
10. Brisk Walking lowers memory loss in women
11. Young womens woes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/30/2016)... , ... April 30, 2016 , ... ... Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ease ... rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture animation, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... News on April 4th, 2016 questioned the use of the HyProCure sinus ... as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when ...
(Date:4/29/2016)... ... ... In an article published April 16th on the New York ... injections, which she underwent in order to feel more at home at this year’s ... article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons say they’ve ...
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a network ... on SB 258, the “Rural Health Care Relief” Bill. , The bill, which was ... individuals and corporations which donate directly to a “rural hospital” in Georgia, and goes ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
Breaking Medicine Technology: